TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24528807

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS) 220kcal
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Corn-soy blend (CSB) 284kcal
Number of subjects: 188

Group type: COMPARATOR
Intervention: No supplements (control)
Number of subjects: 188
Study: 22845008

Group type: EXPERIMENTAL
Intervention: BAF312 dose titration regimen DT1 (0.25-10 mg over 9-10 days)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: BAF312 dose titration regimen DT2 (0.25-10 mg over 9-10 days)
Number of subjects: 56

Group type: COMPARATOR
Intervention: BAF312 non-titration regimen (10 mg starting dose)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 20975325

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBT-G)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Preferred treatment (either Sertraline or CBT-G)
Number of subjects: 145
Study: 18296952

Group type: EXPERIMENTAL
Intervention: Static hamstring stretching (4 repetitions held for 45 seconds, 4 days per week)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no stretching intervention)
Number of subjects: 21
Study: 17136940

Group type: EXPERIMENTAL
Intervention: RC+BD (high-intensity resistance and cardiovascular training and a balanced diet, 40% CHO: 40% PRO)
Number of subjects: 63

Group type: COMPARATOR
Intervention: C+TD (moderate-intensity cardiovascular training and a traditional food guide pyramid diet, CHO 50 to 55%; PRO 15 to 20%; FAT < 30%)
Number of subjects: 63

Group type: COMPARATOR
Intervention: C (inactive control group)
Number of subjects: 63
Study: 12888778

Group type: EXPERIMENTAL
Intervention: ketamine 0.1 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ketamine 0.5 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: saline
Number of subjects: 60
Study: 10730034

Group type: EXPERIMENTAL
Intervention: Rotavirus
Number of subjects: 1526

Group type: EXPERIMENTAL
Intervention: Shigella spp.
Number of subjects: 1526

Group type: EXPERIMENTAL
Intervention: Campylobacter spp.
Number of subjects: 1526

Group type: EXPERIMENTAL
Intervention: Cryptosporidium parvum
Number of subjects: 1526

Group type: EXPERIMENTAL
Intervention: Enteropathogenic Escherichia coli
Number of subjects: 1526

Group type: COMPARATOR
Intervention: Control group (children with other complaints)
Number of subjects: 1526
Study: 8967639

Group type: EXPERIMENTAL
Intervention: Anti-HAV (IgG antibodies against hepatitis A virus)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Anti-HBc (antibodies against hepatitis B virus core antigen)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Anti-HCV (antibodies against hepatitis C virus)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Anti-HEV (antibodies against hepatitis E virus)
Number of subjects: 411
Study: 1547057

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 96
Study: 2932814

Group type: EXPERIMENTAL
Intervention: Bronchodilator (salbutamol 5 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bronchodilator (ipratropium 1 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29808395

Group type: EXPERIMENTAL
Intervention: Children with less depressed parents (N=51 for internalizing, N=38 for externalizing)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Children with more depressed parents (N=28 for internalizing, N=25 for externalizing)
Number of subjects: 142
Study: 30481386

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26918314

Group type: EXPERIMENTAL
Intervention: Orthodontic treatment for Class I malocclusions
Number of subjects: 66

Group type: COMPARATOR
Intervention: Untreated Class I malocclusions (Control)
Number of subjects: 66
Study: 24934787

Group type: EXPERIMENTAL
Intervention: Doxorubicin and cyclophosphamide (AC)
Number of subjects: 3871

Group type: COMPARATOR
Intervention: Single-agent paclitaxel (T)
Number of subjects: 3871
Study: 22052216

Group type: EXPERIMENTAL
Intervention: Face-to-face education on health belief model
Number of subjects: 130
Study: 20214460

Group type: EXPERIMENTAL
Intervention: Nebulized arformoterol 15 microg BID
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Nebulized arformoterol 25 microg BID
Number of subjects: 443

Group type: COMPARATOR
Intervention: Racemic formoterol 12 microg BID
Number of subjects: 443
Study: 18512312

Group type: EXPERIMENTAL
Intervention: PEG‐Asp (2500 IU/m2, intramuscularly once every two weeks for 4 weeks) in VDPAP regimen
Number of subjects: 135

Group type: COMPARATOR
Intervention: L‐asparaginase (6000 IU/m2, three times a week for 2 weeks) in VDLP regimen
Number of subjects: 135
Study: 15860170

Group type: EXPERIMENTAL
Intervention: Close lateral internal sphincterotomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Botulinum toxin (25 U injected into the internal sphincter)
Number of subjects: 80
Study: 12436323

Group type: COMPARATOR
Intervention: Laminectomy (n=13)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Undercutting decompression (n=27)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (Laminectomy)
Number of subjects: 85
Study: 10343464

Group type: EXPERIMENTAL
Intervention: Self-administered PASI (SAPASI)
Number of subjects: 182
Study: 8565513

Group type: EXPERIMENTAL
Intervention: TLC C‐53
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 1844007

Group type: EXPERIMENTAL
Intervention: Modified cow's milk formula (LPM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cow's milk based formula (LP)
Number of subjects: 10
Study: 7075479

Group type: EXPERIMENTAL
Intervention: Viloxazine (Vivalan ICI)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Viloxazine
Number of subjects: 88
Study: 31176242

Group type: EXPERIMENTAL
Intervention: Concept map-based teaching method
Number of subjects: 57

Group type: COMPARATOR
Intervention: Lecture-based teaching method
Number of subjects: 57
Study: 28322416

Group type: EXPERIMENTAL
Intervention: Intensive recruitment strategy (n=157)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Moderate recruitment strategy (n=163)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Intensive recruitment strategy
Number of subjects: 320

Group type: COMPARATOR
Intervention: Moderate recruitment strategy
Number of subjects: 320
Study: 25899896

Group type: EXPERIMENTAL
Intervention: Ginger (2-g ginger rhizomes powder as two 1-g tablets per day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (corn starch with the same amount)
Number of subjects: 80
Study: 23344545

Group type: EXPERIMENTAL
Intervention: HAART (lopinavir/ritonavir/zidovudine/lamivudine or abacavir/zidovudine/lamivudine)
Number of subjects: 730
Study: 21215809

Group type: EXPERIMENTAL
Intervention: Intravenous busulfan (3.2 mg/kg/day)
Number of subjects: 58
Study: 19196357

Group type: EXPERIMENTAL
Intervention: High-protein plan (HP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nutritionally balanced conventional plan (C)
Number of subjects: 75
Study: 16774505

Group type: EXPERIMENTAL
Intervention: Stabilization splint (SS)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Palatal splint (PS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both splints (SS and PS)
Number of subjects: 16
Study: 15504987

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (4 x 40 IU/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11564552

Group type: EXPERIMENTAL
Intervention: Beta-cyclodextrin artemisinin complex
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gamma-cyclodextrin artemisinin complex
Number of subjects: 12

Group type: COMPARATOR
Intervention: Artemisinin 250 (control)
Number of subjects: 12
Study: 9104876

Group type: EXPERIMENTAL
Intervention: Pretraining at 65% VO2peak
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Posttraining at same absolute workload
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Posttraining at same relative workload
Number of subjects: 19
Study: 8217224

Group type: EXPERIMENTAL
Intervention: pH‐stat protocol
Number of subjects: 70

Group type: COMPARATOR
Intervention: alpha‐stat protocol
Number of subjects: 70
Study: 3315535

Group type: EXPERIMENTAL
Intervention: Esaprazole 900 mg/day
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Esaprazole 1350 mg/day
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Esaprazole
Number of subjects: 47
Study: 28902035

Group type: EXPERIMENTAL
Intervention: Small-particle hyaluronic acid (SPHA) injectable gel
Number of subjects: 25
Study: 28918408

Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PDA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implementation of PDA
Number of subjects: 0
Study: 26248362

Group type: EXPERIMENTAL
Intervention: Tafenoquine (TQ)
Number of subjects: 0
Study: 23984051

Group type: EXPERIMENTAL
Intervention: 40 g soy flour (whole soy group)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 40 g low-fat milk powder + 63 mg daidzein (daidzein group)
Number of subjects: 270

Group type: COMPARATOR
Intervention: 40 g low-fat milk powder (placebo group)
Number of subjects: 270
Study: 21389332

Group type: EXPERIMENTAL
Intervention: Glucose at 2 kcal/min (G2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glucose at 3 kcal/min (G3)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glucose at 1 kcal/min (G1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 12
Study: 18312040

Group type: EXPERIMENTAL
Intervention: Enhanced implementation strategy (patient-centered strategy to identify and overcome barriers to adherence)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Basic guideline implementation strategy (usual VA procedures)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Enhanced implementation strategy
Number of subjects: 349
Study: 16546673

Group type: EXPERIMENTAL
Intervention: Dynamic SPECT imaging
Number of subjects: 12

Group type: COMPARATOR
Intervention: Whole-body distribution imaging
Number of subjects: 12

Group type: COMPARATOR
Intervention: Brain SPECT imaging
Number of subjects: 12
Study: 15156935

Group type: EXPERIMENTAL
Intervention: Cranberry extract (2 g daily for 6 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 11448368

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 24
Study: 9729672

Group type: EXPERIMENTAL
Intervention: Strafill NG2 amalgam alloy
Number of subjects: 81

Group type: COMPARATOR
Intervention: googfill 700 amalgam alloy
Number of subjects: 81
Study: 7983122

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 52

Group type: COMPARATOR
Intervention: Patellar retention
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 52
Study: 3292005

Group type: EXPERIMENTAL
Intervention: Subcostal incision (SI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midline incision (C)
Number of subjects: 0
Study: 31749961

Group type: EXPERIMENTAL
Intervention: Training on control of antimicrobial resistance
Number of subjects: 8716

Group type: EXPERIMENTAL
Intervention: Working in a university hospital
Number of subjects: 8716

Group type: EXPERIMENTAL
Intervention: Age classes 26-35 years
Number of subjects: 8716

Group type: EXPERIMENTAL
Intervention: Age classes 36-45 years
Number of subjects: 8716

Group type: EXPERIMENTAL
Intervention: Medical professional status
Number of subjects: 8716

Group type: EXPERIMENTAL
Intervention: Working in an intensive care unit
Number of subjects: 8716
Study: 28374849

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks
Number of subjects: 4629

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 2 weeks
Number of subjects: 4629

Group type: COMPARATOR
Intervention: Control (placebo/ezetimibe)
Number of subjects: 4629

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4629
Study: 26749730

Group type: EXPERIMENTAL
Intervention: Infrapectineal buttress reconstruction plate (group A)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Infrapectineal buttress locking reconstruction plate (group B)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Reconstruction plate combined with trans‐plate quadrilateral screws (group C)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Anterior reconstruction plate‐lag screw (group D)
Number of subjects: 8

Group type: COMPARATOR
Intervention: All groups (A, B, C, D)
Number of subjects: 8
Study: 23276892

Group type: EXPERIMENTAL
Intervention: Preoperative PTCD with bile re‐infusion (n = 56)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conservative treatment alone (n = 60)
Number of subjects: 116
Study: 21607782

Group type: EXPERIMENTAL
Intervention: Jump stress condition
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 18427774

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 40
Study: 16828301

Group type: EXPERIMENTAL
Intervention: Moderate hypothermic cardiopulmonary bypass (CPB) at 31 degrees C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moderate hypothermic cardiopulmonary bypass (CPB) at 32 degrees C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall postoperative mechanical ventilatory support
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall ICU stay
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall hemodynamic improvement
Number of subjects: 30
Study: 14977246

Group type: EXPERIMENTAL
Intervention: Parent‐Adolescent Relationship Education (PARE) Program (experimental education group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention-control group (traditional didactic teaching)
Number of subjects: 0
Study: 10792556

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - transdermal application of continuous 17-beta oestradiol with cyclic medroxyprogesterone acetate tablets every 3rd month for 14 days
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - sequential administration of medroxyprogesterone acetate
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - during medroxyprogesterone administration
Number of subjects: 118
Study: 9065187

Group type: EXPERIMENTAL
Intervention: Gestrinone 2.5 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Gestrinone 1.25 mg
Number of subjects: 11
Study: 2882184

Group type: EXPERIMENTAL
Intervention: Seropositive marrow donors
Number of subjects: 40

Group type: COMPARATOR
Intervention: Seronegative marrow donors
Number of subjects: 40
Study: 29258836

Group type: EXPERIMENTAL
Intervention: Spherical near centred lens (S-CN)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Distance centred lens (CD)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Aspherical near centred lens (A-CN)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All designs
Number of subjects: 150
Study: 27449527

Group type: EXPERIMENTAL
Intervention: G + MH intervention (mental health Internet interventions + gambling intervention)
Number of subjects: 280

Group type: COMPARATOR
Intervention: G‐only intervention (gambling intervention only)
Number of subjects: 280
Study: 23754339

Group type: EXPERIMENTAL
Intervention: Parent-based sleep education
Number of subjects: 80
Study: 24231016

Group type: EXPERIMENTAL
Intervention: Test food containing 300 mg calcium, 150 mg magnesium, and 4.0 g lactulose
Number of subjects: 76

Group type: COMPARATOR
Intervention: Nonintake control group
Number of subjects: 76
Study: 19949010

Group type: EXPERIMENTAL
Intervention: Video intervention after verbal narrative
Number of subjects: 50

Group type: COMPARATOR
Intervention: Verbal narrative (control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 50
Study: 19016185

Group type: EXPERIMENTAL
Intervention: Jinniu capsules
Number of subjects: 212

Group type: COMPARATOR
Intervention: lofexidine
Number of subjects: 212
Study: 16170118

Group type: EXPERIMENTAL
Intervention: New foldable monofocal intraocular lens with flexible haptics
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard foldable intraocular lens
Number of subjects: 40
Study: 14514774

Group type: EXPERIMENTAL
Intervention: Silver iontophoretic catheters
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control catheters
Number of subjects: 268
Study: 11111143

Group type: EXPERIMENTAL
Intervention: Slow-release twice-daily nifedipine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine (without specifying dosage or duration)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (without nifedipine)
Number of subjects: 10
Study: 8656243

Group type: EXPERIMENTAL
Intervention: Mitoxantrone plus prednisone
Number of subjects: 161

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 161
Study: 1893612

Group type: EXPERIMENTAL
Intervention: Sodium chloride (100 mmol slow sodium)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 6358370

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 91

Group type: COMPARATOR
Intervention: Ampicillin and amoxycillin
Number of subjects: 91
Study: 29906525

Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204

Group type: COMPARATOR
Intervention: Pooled Tralokinumab
Number of subjects: 204
Study: 29882722

Group type: EXPERIMENTAL
Intervention: 6-week weighted ball throwing program (2 to 32 ounces), 3 times per week
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 6-week weighted ball throwing program
Number of subjects: 38

Group type: COMPARATOR
Intervention: 5-ounce regulation baseball
Number of subjects: 38
Study: 24995890

Group type: EXPERIMENTAL
Intervention: Adjunctive edivoxetine (6-18 mg once daily)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Adjunctive edivoxetine
Number of subjects: 131

Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 131
Study: 22198479

Group type: EXPERIMENTAL
Intervention: Inspired CO₂
Number of subjects: 10
Study: 21050498

Group type: EXPERIMENTAL
Intervention: Carbon ion radiation therapy (60 Gy E ± 5%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proton radiation therapy (70 Gy E ± 5%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbon ion radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proton radiation therapy
Number of subjects: 0
Study: 17329748

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 12 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 47
Study: 16277771

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (rowed at 55% of maximal aerobic power for 80 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rest (control group)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 8
Study: 12226773

Group type: EXPERIMENTAL
Intervention: Homeopathy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standardised physiotherapy
Number of subjects: 43
Study: 10647571

Group type: EXPERIMENTAL
Intervention: Locked double‐plating construct
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard double‐plating construct
Number of subjects: 12
Study: 9083709

Group type: EXPERIMENTAL
Intervention: Insulin lispro (immediately before each meal)
Number of subjects: 631

Group type: COMPARATOR
Intervention: Regular human insulin (30 to 45 minutes before eating)
Number of subjects: 631
Study: 1362497

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 800 mg cimetidine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 3993320

Group type: EXPERIMENTAL
Intervention: Bupivacaine (22.5 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Glucose-containing bupivacaine (20 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tetracaine (15 mg)
Number of subjects: 21
Study: 30129517

Group type: EXPERIMENTAL
Intervention: Supervised Structured Aerobic Exercise Training (SSAET) program, routine medication, and dietary plan for 25 weeks.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Routine medication and dietary plan for 25 weeks (Control group).
Number of subjects: 102
Study: 27154904

Group type: EXPERIMENTAL
Intervention: 4-week aerobic exercise intervention (3 days/week, combined aerobic and resistance exercise at 70% heart rate reserve)
Number of subjects: 76
Study: 25589316

Group type: COMPARATOR
Intervention: Basic therapy including antibiotics, vessels extending drugs, neuroprotective and detoxification facilities.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cytoflavin 10 ml 0.9% NaCl 200 ml for 10 days, followed by 2 tablets 2 times a day orally for 1 month in addition to basic therapy.
Number of subjects: 60
Study: 22621779

Group type: EXPERIMENTAL
Intervention: Aquacel Ag Hydrofiber dressing
Number of subjects: 112

Group type: COMPARATOR
Intervention: Common dressing
Number of subjects: 112
Study: 20837917

Group type: EXPERIMENTAL
Intervention: Intravenous T3 as Triostat (n=98)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo (n=95)
Number of subjects: 193
Study: 19061712

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF) administered at 10 microg/kg SC for 5 days, followed by leukapheresis and randomized double-blinded intracoronary infusion of CD133+ or unselected cells after 3 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group receiving unselected cells (details not specified)
Number of subjects: 20
Study: 16548348

Group type: EXPERIMENTAL
Intervention: QYJD
Number of subjects: 60

Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 60
Study: 12818601

Group type: EXPERIMENTAL
Intervention: Dimac wires
Number of subjects: 50

Group type: COMPARATOR
Intervention: Arch bars
Number of subjects: 50